Lancet Gastroenterology Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial.Background

The SHINE-1 study explored the potential of mirikizumab, a specialized antibody treatment, for children and adolescents suffering from moderate-to-severe ulcerative colitis who had failed previous therapies. By blocking a specific inflammatory protein known as IL-23, the drug aimed to reduce intestinal damage and provide long-term relief through a sequence of intravenous and subcutaneous doses. The findings revealed that a significant portion of young patients achieved clinical and endoscopic remission by the end of the year-long trial, often without the need for steroids or surgery. While some participants experienced mild side effects like headaches or injection site pain, the overall safety and efficacy results suggest that this treatment is a promising alternative for pediatric patients facing difficult-to-manage bowel disease.